Compare Humana Inc (HUM) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Las Vegas Sands Corp. — how do they compare? Humana Inc trades at $373.38 (market cap $46.31B), while Las Vegas Sands Corp. trades at $45.98 (market cap $29.44B). The key difference: Humana Inc is the larger of the two by market cap, and Las Vegas Sands Corp. pays the higher dividend (2.64%). Which is the better fit depends on your goals.
| HUM | LVS | |
|---|---|---|
Market Cap | $46.31B | $29.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $409.42 | $69.49 |
52-Week Low | $163.67 | $44.78 |
Enterprise Value | $53.67B | $41.33B |
Dividend Yield | 0.92% | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $385.00, up 4.82% today, with a bullish technical outlook and analyst consensus price target of $399.53. Recent earnings beats in Q1 and Q2 2026, alongside revenue growth to $129.66 billion in 2025, support fundamentals, though net margins have compressed. The company is expanding its Medicaid business and targeting margin improvements by 2027.
The stock offers upside to consensus targets but faces risks from Medicare Advantage margin pressures and regulatory changes. Profitability trends are weak despite revenue growth, requiring successful cost management to meet 2028 targets. Institutional sentiment is mixed with a majority hold rating.
LVS trades at $45.77, down 0.74% on the day, with a bearish technical signal and recent Q2 2026 earnings miss. The company shows strong fundamentals with revenue growth to $13.02B in 2025, a net income margin of 12.59%, and robust cash flow from operations of $3.02B. Analyst consensus remains bullish with a $60.75 price target and 59% buy ratings, supported by positive corporate news on ESG achievements and community initiatives.
The outlook for LVS is mixed; strong profitability and analyst optimism contrast with technical bearishness and high debt levels. Upside potential exists if earnings rebound, but risks include competitive pressures and macroeconomic sensitivity. The stock's current valuation at a P/E of 17.74 offers a reasonable entry if operational execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
